Rocket Pharmaceuticals In... (RCKT)
NASDAQ: RCKT
· Real-Time Price · USD
3.19
-0.13 (-3.92%)
At close: Sep 25, 2025, 3:59 PM
3.18
-0.31%
After-hours: Sep 25, 2025, 05:09 PM EDT
-3.92% (1D)
| Bid | 3.19 |
| Market Cap | 344.21M |
| Revenue (ttm) | 9.19M |
| Net Income (ttm) | -257.3M |
| EPS (ttm) | -2.51 |
| PE Ratio (ttm) | -1.27 |
| Forward PE | -2.56 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 3.2 |
| Volume | 1,869,539 |
| Avg. Volume (20D) | 3,857,077 |
| Open | 3.24 |
| Previous Close | 3.32 |
| Day's Range | 3.17 - 3.28 |
| 52-Week Range | 2.19 - 18.92 |
| Beta | 0.62 |
| Ex-Dividend Date | n/a |
About RCKT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RCKT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RCKT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsRocket Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+28.87%
Rocket Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
1 month ago
+4.32%
Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.
4 weeks ago · businesswire.com
Rocket Pharmaceuticals to Participate in Upcoming Investor ConferencesCRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
1 month ago · fool.com
Rocket (RCKT) Q2 Loss Narrows 16%Rocket (RCKT) Q2 Loss Narrows 16%